Pharmacological approaches for Alzheimer’s disease: neurotransmitter as drug targets

References

• Vassallo N, Scerri C. Mediterranean diet and dementia of the Alzheimer type. Curr Aging Sci 2013;6:150-62
   PubMedGoogle Scholar
• Reed TT, Pierce WM, Maresbery WR, Butterfield DA. Proteomic Identification of HNE bound proteins in early Alzheimer’s disease: insight into the role of lipid peroxidationin the progression of AD. Brain Res 2009;1274:66-76
   PubMed Web of Science ®Google Scholar
• Vellas B, Andrieu S, Sampaio C, Wilcock G. Disease-modifying trials in Alzheimer’s disease: a European task force consensus. Lancet Neurol 2007;6:56-62
   PubMed Web of Science ®Google Scholar
• WHO. Dementia: A Public Health Priority. WHO; Geneva: 2012. 112
   Google Scholar
• Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement 2012;8:131-68
   PubMed Web of Science ®Google Scholar
• Barnes DE, Yaffe K. The Projected Impact of Risk Factor Reduction on Alzheimer’s Disease Prevalence. Lancet Neurol 2011;10:819-28
   PubMed Web of Science ®Google Scholar
• Practico D. Evidence of oxidative stress in Alzheimer’s disease brain and antioxidant therapy: lights and shadows. Ann N Y AcadSci 2008;1147:70-8
   PubMedGoogle Scholar
• Michon A. The concept of mild cognitive impairment: relevance and limits in Clinical practice. Front Neurol Neurosci 2009;24:12-29
   PubMedGoogle Scholar
• Bernardi DA, De Jager PL, Leurgans SE, et al. Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles. Neurology 2009;72:1495-503
   PubMedGoogle Scholar
• Placanica L, Zhu L, Li YM. Gender- and age-dependent γ-secretase activity in mouse brain and its implication in sporadic Alzheimer disease. PLoS One 2009;4:e5088
   PubMedGoogle Scholar
• Thal DR, von Arnim C, Griffin WS, et al. Pathology of clinical and preclinical Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 2013;263(Suppl 2):S137-45
   Google Scholar
• Ramirez-Bermudez J. Alzheimer’s disease: critical notes on the history of a medical concept. Arch Med Res 2012;43:595-9
   PubMedGoogle Scholar
• Levenga J, Krishnamurthy P, Rajamohamedsait H, et al. Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments. Acta Neuropathol Commun 2013;1:34
   PubMedGoogle Scholar
• Reinikainen KJ, Soininen H, Riekkinen PJ. Neurotransmitter changes in Alzheimer’s disease: implications to diagnostics and therapy. J Neurosci Res 1990;27:576-86
   PubMedGoogle Scholar
• Drachman DA, Leavitt J. Human memory and the cholinergic system. Arch Neurol 1974;30:113-21
   PubMed Web of Science ®Google Scholar
• Rissman RA, Bennett DA, Armstrong DM. Subregional analysis of GABA(A) receptor subunit mRNAs in the hippocampus of older persons with and without cognitive impairment. J Chem Neuroanat 2004;28:17-25
   PubMedGoogle Scholar
• Francis PT. Lifting the lid: post-mortem brain analysis and Alzheimer’s disease. The Journal of Quality Research in Dementia 2014;4
   Google Scholar
• Martorana A, Mori F, Esposito Z, et al. Dopamine Modulates Cholinergic Cortical Excitability in Alzheimer’s Disease Patients. Neuropsychopharmacology 2009;34:2323-8
   PubMed Web of Science ®Google Scholar
• Limon A, Reyes-Ruiz JM, Miledi R. Loss of functional GABA(A) receptors in the Alzheimer diseased brain. Proc Natl Acad Sci U S A 2012;109:10071-6
   PubMed Web of Science ®Google Scholar
• Borbély E, Scheich B, Helyes Z. Neuropeptides in learning and memory. Neuropeptides 2013;6:439-50
   Google Scholar
• Paris JJ, Eans SO, Mizrachi E, et al. Central administration of angiotensin IV rapidly enhances novel object recognition among mice. Neuropharmacol 2013;70:247-53
   PubMedGoogle Scholar
• Motawaj M, Burban A, Davenas E, et al. Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer’s disease. J Pharmacol Exp Ther 2011;336:479-87
   PubMedGoogle Scholar
• Chen C, Magee JC, Marcheselli V, et al. Attenuated LTP in hippocampal dentate gyrus neurons of mice deficient in the PAF receptor. J Neurophysiol 2001;85:384-90
   PubMedGoogle Scholar
• Diógenes MJ, Costenla AR, Lopes LV, et al. Enhancement of LTP in Aged Rats is Dependent on Endogenous BDNF. Neuropsychopharmacology 2011;36:1823-36
   PubMed Web of Science ®Google Scholar
• Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer’s disease: Past, present and future. Neuropharmacol 2014;76(Pt A):27-50
   PubMed Web of Science ®Google Scholar
• Norimoto H, Mizunuma M, Ishikawa D, et al. Muscarinic receptor activation disrupts hippocampal sharp wave-ripples. Brain Res 2012;1461:1-9
   PubMed Web of Science ®Google Scholar
• Parsons CG, Danysz W, Dekundy A, et al. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox Res 2013;3:358-69
   Google Scholar
• Kato G, Agid Y. Acetylcholine receptors (author’s transl.). Nouv Presse Med 1979;8:2407-11
   PubMedGoogle Scholar
• Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain. Prog Neurobiol 2000;61:75-111
   PubMed Web of Science ®Google Scholar
• Garduno J, Charles LG, Rodríguez JJ, et al. Presynaptic42 Nicotinic Acetylcholine Receptors Increase Glutamate Release and Serotonin Neuron Excitability in the Dorsal Raphe Nucleus. J Neurosci 2012;32:15148-57
   PubMed Web of Science ®Google Scholar
• Buckingham SD, Jones AK, Brown LA, et al. Nicotinic Acetylcholine Receptor Signalling: roles in Alzheimer’s Disease and Amyloid Neuroprotection. Pharmacol Rev 2009;61:39-61
   PubMed Web of Science ®Google Scholar
• Schröder H, Giacobini E, Struble RG, et al. Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer’s Disease. Neurobiol Aging 1991;12:259-62
   PubMed Web of Science ®Google Scholar
• Levin ED, Perkins A, Brotherton T, et al. Chronic underactivity of medial frontal cortical β2-containing nicotinic receptors increases clozapine-induced working memory impairment in female rats. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:296-302
   PubMedGoogle Scholar
• Tsang SW, Lai MK, Kirvell S, et al. Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer’s disease. Neurobiol Aging 2006;27:1216-23
   PubMed Web of Science ®Google Scholar
• Heo YM, Shin MS, Lee JM, et al. Treadmill exercise ameliorates short-term memory disturbance in scopolamine-induced amnesia rats. Int Neurol J 2014;18:16-22
   PubMedGoogle Scholar
• Higgins JP, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev 2003;CD001015
   Google Scholar
• Penry JT, Manore M. Choline: an important micronutrient for maximal endurance-exercise performance? Int J Sport Nutr Exerc Metab 2008;18:191-203
   PubMed Web of Science ®Google Scholar
• Wurtman RJ, Cansev M, Ulus IH. Choline and Its Products Acetylcholine and Phosphatidylcholine. Handbook of Neurochemistry and Molecular Neurobiology. Springer; US: 2010. pp 443-501
   Google Scholar
• Cohen EL, Wurtman RJ. Brain acetylcholine: increase after systemic choline administration. Life Sci 1975;16:1095-102
   PubMed Web of Science ®Google Scholar
• Cohen EL, Wurtman RJ. Brain acetylcholine: control by dietary choline. Science 1976;191:561-2
   PubMed Web of Science ®Google Scholar
• Amenta F, Tayebati SK. Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction. Curr Med Chem 2008;15:488-98
   PubMed Web of Science ®Google Scholar
• Lanctôt KL, Rajaram RD, Herrmann N. Therapy for Alzheimer’s disease: how effective are current treatments? Ther Adv Neurol Disord 2009;2:163-80
   PubMedGoogle Scholar
• Barar FSK. Essentials of Pharmacotherapeutics, Antiparkinsonian drugs. 4th Edition. S. Chand and Company Ltd; New Delhi: 2007. 169
   Google Scholar
• Farlow M, Veloso F, Moline M, et al. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease. BMC Neurol 2011;11:57
   PubMed Web of Science ®Google Scholar
• Akasofu S, Kimura M, Kosasa T, et al. Study of neuroprotection of donepezil, a therapy for Alzheimer’s disease. Chem Biol Interact 2008;175:222-6
   PubMed Web of Science ®Google Scholar
• Takada Y, Yonezawa A, Kume T, et al. Nicotinic acetycholine receptor mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 2003;306:772-7
   PubMed Web of Science ®Google Scholar
• Fisher A. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer’s disease. Neurotherapeutics 2008;5:433-42
   PubMed Web of Science ®Google Scholar
• Caccamo A, Oddo S, Billings LM, et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006;49:671-82
   PubMed Web of Science ®Google Scholar
• Hock C, Maddalena A, Raschig A, et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer’s disease. Amyloid 2003;10:1-6
   PubMed Web of Science ®Google Scholar
• Heinrich JN, Butera JA, Carrick T, et al. Pharmacological comparisons of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol 2009;605:53-6
   PubMedGoogle Scholar
• Sadashiva CT, Chandra JN, Kavitha CV, et al. Synthesis and pharmacological evaluation of novel N-alkyl/aryl substituted thiazolidinone arecoline analogues as muscarinic receptor 1 agonist in Alzheimer’s dementia models. Eur J Med Chem 2009;44:4848-54
   PubMed Web of Science ®Google Scholar
• Malviya M, Kumar YC, Mythri RB, et al. Muscarinic receptor 1 agonist activity of novel N-aryl carboxamide substituted 3-morpholino arecoline derivatives in Alzheimer’s presenile dementia models. Bioorg Med Chem 2009;17:5526-34
   PubMed Web of Science ®Google Scholar
• Malviya M, Kumar YC, Asha D, et al. Muscarinic receptor 1 agonist activity of novel N-arylthioureas substituted 3-morpholino arecoline derivatives in Alzheimer’s presenile dementia models. Bioorg Med Chem 2008;16:7095-101
   PubMedGoogle Scholar
• Kumar YC, Malviya M, Chandra JN, et al. Effect of novel N-aryl sulfonamide substituted 3-morpholino arecoline derivatives as muscarinic receptor 1 agonists in Alzheimer’s dementia models. Bioorg Med Chem 2008;16:5157-63
   PubMed Web of Science ®Google Scholar
• Dunbar GC, Inglis F, Kuchibhatla R, et al. Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). J Psychopharmacol 2007;21:171-8
   PubMed Web of Science ®Google Scholar
• Baker JD, Lenz RA, Locke C, et al. ABT-089, a neuronal nicotinic receptor partial agonist, reverses scopolamine-induced cognitive deficits in healthy normal subjects. Alzheimers Dement 2009;5(4 suppl 1):P325
   Google Scholar
• Nie H, Wang Z, Zhao W, et al. New nicotinic analogue ZY-1 enhances cognitive functions in a transgenic mice model of Alzheimer’s disease. Neurosci Lett 2013;537:29-34
   PubMedGoogle Scholar
• Dajas-Bailador F, Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci 2004;25:317-24
   PubMed Web of Science ®Google Scholar
• Broide RS, Leslie FM. The α7 nicotinic acetylcholine receptor in neuronal plasticity. Mol Neurobiol 1999;20:1-16
   PubMed Web of Science ®Google Scholar
• Berg DK, Conroy WG. Nicotinic α7 receptors: synaptic options and downstream signaling in neurons. J Neurobiol 2002;53:512-23
   PubMedGoogle Scholar
• Hashimoto K, Hattori E, Part II. Candidate Gene and Models. 4. Neurotransmission. In: Neurogenetics of Psychiatric Disorders. Sawa A, McInnis MG, Editors Informa Healthcare; New York: 2007. pp. 81-100
   Google Scholar
• Ikonomovic MD, Wecker L, Abrahamson EE, et al. Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease. Arch Neurol 2009;66:646-51
   PubMedGoogle Scholar
• Ni R, Marutle A, Nordberg A. Modulation of α7 nicotinic acetylcholine receptor and fibrillar amyloid-β interactions in Alzheimer’s disease brain. J Alzheimers Dis 2013;33:841-51
   PubMedGoogle Scholar
• Oz M, Lorke DE, Yang KH, et al. On the interaction of β-amyloid peptides and α7-nicotinic acetylcholine receptors in Alzheimer’s disease. Curr Alzheimer Res 2013;10:618-30
   PubMedGoogle Scholar
• Liu QS, Kawai H, Berg DK. β-Amyloid peptide blocks the response of α7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci USA 2001;48:4734-9
   Google Scholar
• Pettit DL, Shao Z, Yakel JL. β-Amyloid1-42 peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci 2001;21(RC120):1-5
   Google Scholar
• Lee DH, Wang HY. Differential physiologic responses of α7 nicotinic acetylcholine receptors to β-amyloid1-40 and β-amyloid1-42. J Neurobiol 2003;55:25-30
   PubMedGoogle Scholar
• Wang HY, Lee DH, Davis CB, et al. Amyloid peptide Aβ1-42 binds selectively and with pico-molar affinity to α7 nicotinic acetylcholine receptors. J Neurochem 2000;75:1155-61
   PubMed Web of Science ®Google Scholar
• Kem WR. The brain α7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer’s disease: studies with DMXBA (GTS-21). Behav Brain Res 2000;113:169-81
   PubMed Web of Science ®Google Scholar
• Zawieja P, Kornprobst JM, Métais P. 3-(2,4-dimethoxybenzylidene)-anabaseine: a promising candidate drug for Alzheimer’s disease? Geriatr Gerontol Int 2012;12:365-71
   PubMedGoogle Scholar
• Vicens P, Ribes D, Heredia L, et al. Motor and anxiety effects of PNU-282987, an alpha7 nicotinic receptor agonist, and stress in an animal model of Alzheimer’s disease. Curr Alzheimer Res 2013;10:516-23
   PubMed Web of Science ®Google Scholar
• Lucas DR, Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch Ophthalmol 1957;58:193-201
   PubMed Web of Science ®Google Scholar
• Kallarackal AJ, Kvarta MD, Cammarata E, et al. Chronic stress induces a selective decrease in AMPA receptor-mediated synaptic excitation at hippocampal temporoammonic-CA1 synapses. J Neurosci 2013;33:15669-74
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Pocernich CB. The Glutamatergic System and Alzheimer’s Disease. CNS Drugs 2003;17:641-52
   PubMed Web of Science ®Google Scholar
• Huganir RL, Nicoll RA. AMPARs and Synaptic Plasticity: the Last 25 Years. Neuron 2013;80:704-17
   PubMed Web of Science ®Google Scholar
• Filliat P, Blanchet G. Effects of TCP on spatial memory: comparison with MK-801. Pharmacol Biochem Behav 1995;51:429-34
   PubMedGoogle Scholar
• Hynd M, Scott H, Dodd P. Glutamate mediated excitotoxicity and neurodegeneration in Alzheimer’s disease. Neurochem Int 2004;45:583-95
   PubMed Web of Science ®Google Scholar
• Henry WQ, Frank ML. Alzheimer’s disease: the mechanism of disease. N Engl J Med 2010;362:329-44
   PubMed Web of Science ®Google Scholar
• Wilkinson D, Wirth Y, Goebel C. Memantine in Patients with Moderate to Severe Alzheimer’s Disease: meta-Analyses Using Realistic Definitions of Response. Dement Geriatr Cogn Disord 2013;37:71-85
   PubMedGoogle Scholar
• Jarvis B, Figgitt DP. Memantine. Drugs Aging 2003;20:465-76
   PubMed Web of Science ®Google Scholar
• Geldenhuys WJ, Van der Schyf CJ. Role of serotonin in Alzheimer’s disease: a new therapeutic target? CNS Drugs 2011;25:765-81
   PubMed Web of Science ®Google Scholar
• Meltzer CC, Smith G, DeKosky ST, et al. Serotonin in aging, late-life depression, and Alzheimer’s disease: the emerging role of functional imaging. Neuropsychopharmacology 1998;18:407-30
   PubMed Web of Science ®Google Scholar
• Bajwa A, Patel H, Pan ML. Christopher Liang and Jogeshwar Mukherjee. Evaluation of serotonin 5HT1A receptors in postmortem Alzheimer’s disease brains. J Nucl Med 2013;54:1791
   Google Scholar
• Lai MKP, Tsang SWY, Francis PT, et al. Postmortem serotoninergic correlates of cognitive decline in Alzheimer’s disease. Neurreport 2002;13:1175-8
   PubMedGoogle Scholar
• Whitford GM. Alzheimer’s Disease and Serotonin: a Review. Pharmacopsychiatry 1986;15:3-4
   Google Scholar
• Hardy J, Adolfsson R, Alafuzoff I, et al. Transmitter deficits in Alzheimer’s disease. Neurochem Int 1985;7:545-63
   PubMed Web of Science ®Google Scholar
• Hoyer D, Martin G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacol 1997;36:419-28
   PubMed Web of Science ®Google Scholar
• Yunqi Xu, Junqiang Yan, Peng Zhou. Neurotransmitter receptors and cognitive dysfunction in Alzheimer’s disease and Parkinson’s disease. Prog Neurobiol 2012;97:1-13
   PubMedGoogle Scholar
• Schechter LE, Dawson LA, Harder JA. The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer s disease. Curr Pharm Des 2002;8:139-45
   PubMedGoogle Scholar
• Schechter LE, Smith DL, Rosenzweig-Lipson S, Sukoff SJ. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive enhancing properties. J Pharmacol Exp Ther 2005;314:1274-89
   PubMed Web of Science ®Google Scholar
• Patat A, Parks V, Raje S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects. Br J Clin Pharmacol 2009;67:299-308
   PubMed Web of Science ®Google Scholar
• Upton N, Chuang TT, Hunter AJ, et al. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease. Neurotherapeutics 2008;5:458-69
   PubMed Web of Science ®Google Scholar
• Marazziti D, Baroni S, Pirone A, et al. Serotonin receptor of type 6 (5-HT6) in human prefrontal cortex and hippocampus post-mortem: an immunohistochemical and immunofluorescence study. Neurochem Int 2012;62(2):182-8
   PubMedGoogle Scholar
• Schechter LE, Lin Q, Smith DL, et al. Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology 2008;33:1323-35
   PubMed Web of Science ®Google Scholar
• West PJ, Marcy VR, Marino MJ, et al. Activation of the 5-HT (6) receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus. Neurosci 2009;164:692-701
   PubMed Web of Science ®Google Scholar
• Codony X, Vela JM, Ramírez MJ. 5-HT (6) receptor and cognition. Curr Opin Pharmacol 2011;11:94-100
   PubMed Web of Science ®Google Scholar
• Martorana A, Di Lorenzo F, Esposito Z, et al. Dopamine D2-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer’s disease patients. Neuropharmacol 2013;64:108
   PubMed Web of Science ®Google Scholar
• Sesack SR, Grace AA. Cortico-Basal Ganglia Reward Network: microcircuitry. Neuropsychopharmacology REVIEWS 2010;35:27-47
   PubMed Web of Science ®Google Scholar
• Zhang L, Doyon WM, Clark JJ, et al. Controls of tonic and phasic dopamine transmission in the dorsal and ventral striatum. Mol Pharmacol 2009;76:2-396-404
   Google Scholar
• Hosp JA, Molina-Luna K, Hertler B, et al. Dopaminergic modulation of motor maps in rat motor cortex: an in vivo study. Neurosci 2009;159:692-700
   PubMed Web of Science ®Google Scholar
• Molina-Luna K, Pekanovic A, Röhrich S, et al. Dopamine in motor cortex is necessary for skill learning and synaptic plasticity. PLoS One 2009;4:7082
   PubMed Web of Science ®Google Scholar
• McCormick AV, Wheeler JM, Guthrie CR, et al. Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity. Biol Psychiatry 2013;73:464-71
   PubMed Web of Science ®Google Scholar
• Sesack SR, Grace AA. Cortico-basal ganglia reward network: microcircuitry. Neuropsychopharmacology 2010;35:27-47
   PubMed Web of Science ®Google Scholar
• Cytril G, Valerio M, Marc L, et al. Metabotropic receptors for glutamate and GABA in pain. Brain Res Rev 2009;S60:43-56
   Google Scholar
• Eduardo EB. GABAB receptors Structure, functions, and clinical implications. Neurology 2012;78:578-84
   PubMedGoogle Scholar
• Zarrindast MR, Bakhsha A, Rostami P, et al. Effects of intrahippocampal injection of GABAergic drugs on memory retention of passive avoidance learning in rats. J Psychopharmacol 2002;16:313-19
   PubMed Web of Science ®Google Scholar
• Oblak AL, Gibbs TT, Blatt GJ. Decreased GABAB receptors in the cingulate cortex and fusiform gyrus in autism. J Neurochem 2010;114:1414-23
   PubMed Web of Science ®Google Scholar
• Froestl W, Gallagher M, Jenkins H, et al. SGS742: the first GABAB receptor antagonist in clinical trials. Biochem Pharm 2004;68:1479-87
   PubMed Web of Science ®Google Scholar
• Helm KA, Haberman RP, Dean SL, et al. GABAB receptor antagonist SGS742 improves spatial memory and reduces protein binding to the cAMP response element (CRE) in the hippocampus. Neuropharmacol 2005;48:956-64
   PubMed Web of Science ®Google Scholar
• Berta S, Ki-Shuk S, Gunyong A, et al. Hippocampal levels of phosphorylated protein kinase a (phosphor-S96) are linked to spatial memory enhancement by SGS742. Hippocampus 2009;19:90-8
   PubMedGoogle Scholar
• Craig MT, Mayne EW, Bettler B, et al. Distinct roles of GABAB1a- and GABAB1b-containing GABAB receptors in spontaneous and evoked termination of persistent cortical activity. J Physiol 2013;591:835-43
   PubMedGoogle Scholar
• Marcade M, Bourdin J, Loiseau N, et al. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem 2008;106:392-404
   PubMed Web of Science ®Google Scholar
• Nuutinen S, Panula P. Histamine in neurotransmission and brain diseases. Adv Exp Med Biol 2011;709:95-107
   Google Scholar
• Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol 2001;63:637-72
   PubMed Web of Science ®Google Scholar
• Medhurst AD, Roberts JC, Lee J, et al. Characterization of histamine H3 receptors in Alzheimer’s Disease brain and amyloid over-expressing TASTPM mice. Br J Pharmacol 2009;157:130-8
   PubMed Web of Science ®Google Scholar
• Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983;28:832-7
   Google Scholar
• Chazot PL. Therapeutic potential of histamine H3 receptor antagonists in dementias. Drug News Perspect 2010;23:99-103
   PubMedGoogle Scholar
• Da Silveira CK, Furini CR, Benetti F, et al. The role of histamine receptors in the consolidation of object recognition memory. Neurobiol Learn Mem 2013;103:64-71
   PubMed Web of Science ®Google Scholar
• Ligneau X, Perrin D, Landais L. BF2.649 [1-{3-[3-(4- Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther 2007;320:365-75
   PubMed Web of Science ®Google Scholar
• Soares H, Wagner T, Schmidt A. H3 receptor antagonism increases methylhistamine level in the cerebrospinal fluid of dogs and healthy human volunteers. in International Conference on Alzheimer’s Disease (ICAD). 2009. Vienna
   Google Scholar
• Iannone R, Renger J, Potter W, et al. The relationship between brain receptor occupancy (RO) and alerting effects in humans support MK-0249 and MK-3134 as inverse agonists at the histamine subtype-3 pre-synaptic receptor (H3R). 48th Meeting of the ACNP Hollywood; 2009. Florida
   Google Scholar
• Medhurst A, Atkins A, Beresford I, et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer’s disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 2007;321:1032-45
   PubMed Web of Science ®Google Scholar
• Brioni JD, Esbenshade TA, Garrison TR, et al. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer’s disease. J Pharmacol Exp Ther 2011;336:38-46
   PubMed Web of Science ®Google Scholar
• Othman AA, Haig G, Florian H. Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers. Br J Clin Pharmacol 2013;75:1299-311
   PubMed Web of Science ®Google Scholar
• Nathan PJ, Boardley R, Scott N, et al. The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H3 receptor antagonist in patients with mild to moderate Alzheimer’s disease: a preliminary investigation. Curr Alzheimer Res 2013;10:240-51
   PubMed Web of Science ®Google Scholar
• Griebel G, Pichat P, Pruniaux MP, et al. SAR110894, a potent histamine H3-receptor antagonist, displays procognitive effects in rodent. Pharmacol Biochem Behav 2012;102:203-14
   PubMed Web of Science ®Google Scholar
• Van Ruitenbeek P, Mehta MA. Potential enhancing effects of histamine H1 agonism/H3 antagonism on working memory assessed by performance and bold response in healthy volunteers. Br J Pharmacol 2013;170:144-55
   PubMedGoogle Scholar
• Rapoport SI. Brain arachidonic and docosahexaenoic acid cascades are selectively altered by drugs, diet and disease. Prostaglandins Leukot Essent Fatty Acids 2008;79:153-6
   PubMed Web of Science ®Google Scholar
• Choi SH, Bosetti F. Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging (Albany NY) 2009;1:234-44
   PubMedGoogle Scholar
• Kaufmann WE, Worley PF, Pegg J, et al. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 1996;93:2317-21
   PubMed Web of Science ®Google Scholar
• Kumar P, Kalonia H, Kumar A. Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington’s Disease-like symptoms in rats: protective effect of licofelone. Br J Pharmacol 2011;164(2b):644-54
   PubMed Web of Science ®Google Scholar
• Ryu JK, Franciosi S, Sattayaprasert P, et al. Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus. Glia 2004;48:85-90
   PubMed Web of Science ®Google Scholar
• Androsova LV, Mikhaîlova NM, Zozulia SA, et al. Inflammatory markers in Alzheimer’s disease and vascular dementia. Zh Nevrol Psikhiatr Im S S Korsakova 2013;113:49-53
   PubMedGoogle Scholar
• Fujimi K, Noda K, Sasaki K, et al. Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer’s disease: the Hisayama Study. Dement Geriatr Cogn Disord 2007;23:423-31
   PubMed Web of Science ®Google Scholar
• Manev H, Chen H, Dzitoyeva S, et al. Cyclooxygenases and 5-lipoxygenase in Alzheimer’s disease. Prog Neuro-Psychopharmacol Biol Psychiatry 2011;35:315-19
   PubMedGoogle Scholar
• Scali C, Giovannini MG, Prosperi C, et al. The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. Neurosci 2003;117:909-19
   PubMed Web of Science ®Google Scholar
• Choi SH, Aid S, Caracciolo L, et al. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer’s disease. J Neurochem 2013;124:59-68
   PubMed Web of Science ®Google Scholar
• Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci 2000;20:5709-14
   PubMed Web of Science ®Google Scholar
• Zurita MP, Muñoz G, Sepúlveda FJ, et al. Ibuprofen inhibits the synaptic failure induced by the amyloid-β peptide in hippocampal neurons. J Alzheimers Dis 2013;35:463-73
   PubMedGoogle Scholar
• Côté S, Carmichael PH, Verreault R, et al. Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer’s disease. Alzheimers Dement 2012;8:219-26
   PubMedGoogle Scholar
• Wright JW, Harding JW. Harding. Brain renin-angiotensin—A new look at an old system. Prog Neurobiol 2011;95:49-67
   PubMed Web of Science ®Google Scholar
• Littlejohn NK, Siel RBJr, Ketsawatsomkron P, et al. Hypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependent. Am J Physiol Regul Integr Comp Physiol 2013;304:R818-28
   Google Scholar
• Barnes NM, Champaneria S, Costall B, et al. Cognitive enhancing actions of DuP 753 detected in a mouse habituation paradigm. Neuroreport 1990;1(3-4):239-42
   PubMedGoogle Scholar
• Singh B, Sharma B, Jaggi AS, et al. Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer’s disease type: possible involvement of PPAR-γ agonistic property. J Renin Angiotensin Aldosterone Syst 2013;14:124-36
   PubMed Web of Science ®Google Scholar
• Yonkov D, Georgiev V, Kambourova T. Further evidence for the GABAergic influence on memory. Interaction of GABAergic transmission with angiotensin II on memory processes. Methods Find Exp Clin Pharmacol 1989;11:603-6
   PubMedGoogle Scholar
• Wilson WL, Munn C, Ross RC, et al. The role of the AT4 and cholinergic systems in the Nucleus Basalis Magnocellularis (NBM): effects on spatial memory. Brain Res 2009;1272:25-31
   PubMedGoogle Scholar
• Wright JW, Stubley L, Pederson ES, et al. Contributions of the brain angiotensin IV–AT4 receptor subtype system to spatial learning. J Neurosci 1999;19:3952-61
   PubMedGoogle Scholar
• Chai SY, Bastias MA, Clune EF, et al. Distribution of angiotensin IV binding sites (AT4 receptor) in the human forebrain, midbrain and pons as visualised by in vitro receptor autoradiography. J Chem Neuroanat 2000;20:339-48
   PubMedGoogle Scholar
• Olson ML, Olson EA, Qualls JH, et al. Norleucine1 Angiotensin IV alleviates mecamylamine-induced spatial memory deficits. Peptides 2004;2:233-41
   Google Scholar
• Paul V, Ekambaram P. Involvement of nitric oxide in learning & memory processes. Indian J Med Res 2011;133:471-8
   PubMed Web of Science ®Google Scholar
• Harooni HE, Naghdi N, Sepehri H, et al. The role of hippocampal nitric oxide on learning and immediate short and long-term memory retrieval in inhibitory avoidance task in male adult rats. Behav Brain Res 2009;201:166-72
   PubMed Web of Science ®Google Scholar
• Zhihui Q. Modulating nitric oxide signaling in the CNS for Alzheimer’s disease therapy. Future Med Chem 2013;5:1451-68
   PubMed Web of Science ®Google Scholar
• Fernandez AP, Pozo-Rodrigalvarez A, Serrano J, et al. Nitric oxide: target for therapeutic strategies in Alzheimer’s disease. Curr Pharm Des 2010;16:2837-50
   PubMed Web of Science ®Google Scholar
• Xu X, Russel T, Bazner J, et al. NMDA receptor antagonist AP5 and nitric oxide synthase inhibitor 7-NI affect different phase of learning and memory in gold fish. Brain Res 2001;889:274-7
   PubMedGoogle Scholar
• Yildiz Akar E, Ulak G, Tanyer P, et al. 7-nitroindazole, a neuronal nitric oxide synthase inhibitor impairs passive-avoidance and elevated plus-maze memory performance in rats. Pharmacol Biochem Behav 2007;87:434-43
   PubMedGoogle Scholar
• Sweatt JD. Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol 2004;14:311-17
   PubMed Web of Science ®Google Scholar
• Calissano P, Matrone C, Amadoro G. Nerve growth factor as a paradigm of neurotrophins related to Alzheimer’s disease. Dev Neurobiol 2010;70:372-83
   PubMed Web of Science ®Google Scholar
• Venero JL, Knusel B, Beck KD, et al. Expression of neurotrophin and trk receptor genes in adult rats with fimbria transections: effect of intraventricular nerve growth factor and brain-derived neurotrophic factor administration. Neurosci 1994;59:797-815
   PubMedGoogle Scholar
• Weissmiller AM, Wu C. Current advances in using neurotrophic factors to treat neurodegenerative disorders. Translational Neurodegeneration 2012;1:14
   PubMedGoogle Scholar
• Nabeshima T. Nerve growth factor strategy and preparation of animal model for Alzheimer-type senile dementia. Yakugaku Zasshi 1995;115:499-512
   PubMed Web of Science ®Google Scholar
• Caraci F, Spampinato S, Sortino MA, et al. Dysfunction of TGF-β1 signaling in Alzheimer’s disease: perspectives for neuroprotection. Cell Tissue Res 2012;347:291-301
   PubMed Web of Science ®Google Scholar
• Caraci F, Battaglia G, Busceti C, et al. TGF-beta 1 protects against Abeta-neurotoxicity via the phosphatidylinositol-3-kinase pathway. Neurobiol Dis 2008;30:234-42
   PubMed Web of Science ®Google Scholar
• Sortino MA, Chisari M, Merlo S, et al. Glia mediates the neuroprotective action of estradiol on beta-amyloid induced neuronal death. Endocrinology 2004;145:5080-6
   PubMed Web of Science ®Google Scholar
• Goeldner C, Ballard TM, Knoflach F, et al. Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Neuropharmacol 2013;64:337-46
   PubMed Web of Science ®Google Scholar
• Caraci F, Battaglia G, Bruno V, et al. TGF-β1 pathway as a new target for neuroprotection in Alzheimer’s disease. CNS Neurosci Ther 2011;17:237-49
   PubMed Web of Science ®Google Scholar
• Vollmar P, Haghikia A, Dermietzel R, et al. Venlafaxine exhibits an anti-inflammatory effect in an inflammatory co-culture model. Int J Neuropsychopharmacol 2008;11:111-17
   PubMedGoogle Scholar
• Alcalay RN, Giladi E, Pick CG, et al. Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett 2004;361:128-31
   PubMed Web of Science ®Google Scholar
• Gozes I, Divinski I, Piltzer I. NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42). BMC Neurosci 2008;9(Suppl 3):S3
   PubMedGoogle Scholar
• Fernandez-Montesinos R, Torres M, Baglietto-Vargas D, et al. Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer’s disease. J Mol Neurosci 2010;41:114-20
   PubMedGoogle Scholar
• Brenneman DE, Gozes I. A femtomolar-acting neuroprotective peptide. J Clin Invest 1996;97:2299-307
   PubMed Web of Science ®Google Scholar
• Glazner GW, Boland A, Dresse AE, et al. Activity-dependent neurotrophic factor peptide (ADNF9) protects neurons against oxidative stress-induced death. J Neurochem 1999;73:2341-7
   PubMed Web of Science ®Google Scholar
• Blondel O, Collin C, McCarran WJ, et al. A glia-derived signal regulating neuronal differentiation. J Neurosci 2000;20:8012-20
   PubMed Web of Science ®Google Scholar
• Bassan M, Zamostiano R, Davidson A, et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 1999;72:1283-93
   PubMed Web of Science ®Google Scholar
• Gozes I, Zaltzman R, Hauser J, et al. The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Curr Alzheimer Res 2005;2:149-53
   PubMedGoogle Scholar
• Vulih-Shultzman I, Pinhasov A, Mandel S, et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther 2007;323:438-49
   PubMed Web of Science ®Google Scholar
• Divinski I, Mittelman L, Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 2004;279:28531-8
   PubMed Web of Science ®Google Scholar
• Visochek L, Steingart RA, Vulih-Shultzman I, et al. PolyADP-ribosylation is involved in neurotrophic activity. J Neurosci 2005;25:7420-8
   PubMedGoogle Scholar
• Mironov SL, Ivannikov MV, Johansson M. [Ca2+]i signaling between mitochondria and endoplasmic reticulum in neurons is regulated by microtubules. From mitochondrial permeability transition pore to Ca2+-induced Ca2+ release. J Biol Chem 2005;280:715-21
   PubMed Web of Science ®Google Scholar
• Izquierdo I, Fin C, Schmitz PK, et al. Memory enhancement by intrahippocampal, intraamygdala, or intraentorhinal infusion of platelet-activating factor measured in an inhibitory avoidance task. Proc Natl Acad Sci U S A 1995;92:5047-51
   PubMedGoogle Scholar
• Hu XL, Xiao HM, Hu XW, et al. Influence of PAF receptors on long term potentiation attenuated by aluminium in hippocampal CA3 area of rats. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2004;20:161-5
   PubMedGoogle Scholar
• Packard MG, Teather LA, Bazan NG. Effects of intrastriatal injections of platelet-activating factor and the PAF antagonist BN 52021 on memory. Neurobiol Learn Mem 1996;66:176-82
   PubMedGoogle Scholar
• Singh N, Sharma A, Singh M. Effects of BN-50730 (PAF receptor antagonist) and physostigmine (AChE inhibitor) on learning and memory in mice. Methods Find Exp Clin Pharmacol 1997;19:585-8
   PubMedGoogle Scholar
• Van Dam D, Van Dijck A, Janssen L, et al. Neuropeptides in Alzheimer’s Disease: from Pathophysiological Mechanisms to Therapeutic Opportunities. Curr Alzheimer Res 2013;10:449-68
   PubMedGoogle Scholar
• Tiwari SK, Chaturvedi RK. Peptide therapeutics in neurodegenerative disorders. Curr Med Chem 2014;21(23):2610-31
   PubMedGoogle Scholar
• Pan YF, Jia XT, Wang XH, et al. Arginine vasopressin remolds the spontaneous discharges disturbed by amyloid β protein in hippocampal CA1 region of rats. Regul Pept 2013;183C:7-12
   Google Scholar
• Pan YF, Chen XR, Wu MN, et al. Arginine vasopressin prevents against Abeta (25-35)-induced impairment of spatial learning and memory in rats. Horm Behav 2010;57:448-54
   PubMedGoogle Scholar
• Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, estrogen, and dementia: A 2014 update. Mol Cell Endocrinol 2014;389(1-2):7-12
   PubMed Web of Science ®Google Scholar
• Yin QQ, Pei JJ, Xu S, et al. Pioglitazone Improves Cognitive Function via Increasing Insulin Sensitivity and Strengthening Antioxidant Defense System in Fructose-Drinking Insulin Resistance Rats. 2013;10:1371
   Google Scholar
• Sørensen AT, Kanter-Schlifke I, Lin EJ, et al. Activity-dependent volume transmission by transgene NPY attenuates glutamate release and LTP in the subiculum. Mol Cell Neurosci 2008;39:229-37
   PubMedGoogle Scholar
• Flood JF, Baker ML, Hernandez EN, et al. Modulation of memory retention by neuropeptide K. Brain Res 1990;520:284-90
   PubMedGoogle Scholar
• Medicines in Development for Neurological Disorders, A Report on Disorders of the Brain, Spinal Cord and Nerves presented by America’s biopharmaceutical research companies; 2013 report. Available from: www.phrma.org/sites/default/files/Alzheimer’s%202013.pdf
   Google Scholar
• Medicines in Development for Older Americans, The Medicare Population and Leading Chronic Diseases presented by America ’s biopharmaceutical research companies. 2013 report
   Google Scholar
• Wildburger NC, Lin-Ye A, Baird MA, et al. Neuroprotective effects of blockers for T-type calcium channels. Mol Neurodegener 2009;4:44
   PubMedGoogle Scholar
• Barret MJ. Calcium channel blockers and Parkinson disease. Medscape.boards.forum. Data retrieved on 8 June 2014
   Google Scholar
• Huang BR, Chang PC, Yeh WL, et al. Anti-neuroinflammatory effects of the calcium channel blocker nicardipine on microglial cells: implications for neuroprotection. PLoS One 2014.9:3. Available from: www.plosone.org
   Google Scholar
• A Phase III Trial of Nilvadipine to Treat Alzheimer’s Disease (NILVAD). Available from: http://clinicaltrials.gov/show/NCT02017340
   Google Scholar
• Watt AD, Crespi GA, Down RA, et al. Do current therapeutic anti-Aβ antibodies for Alzheimer’s disease engage the target? Acta Neuropathol 2014;127:803-10
   PubMed Web of Science ®Google Scholar
• Panza F, Frisardi V, Imbimbo BP, et al. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer’s disease: the Aβ target at a crossroads. Expert Opin Biol Ther 2011;11:679-86
   PubMed Web of Science ®Google Scholar
• Okun I, Tkachenko SE, Khvat A, et al. From anti-allergic to anti-Alzheimer’s: molecular pharmacology of Dimebon. Curr Alzheimer Res 2010;2:97-112
   Google Scholar
• Editorial. Mechanism matters. Nat Med 2010;16:4
   Google Scholar
• Yun H, Rhim H. The Serotonin-6 Receptor as a Novel Therapeutic Target. ExpNeurobiol 2011;20:159-68
   Google Scholar
• Study of Lu AE58054 in Patients With Mild - Moderate Alzheimer’s Disease Treated With Donepezil (STARSHINE). 2014. Available from: http://www.clinicaltrials.gov/show/NCT01955161
   Google Scholar
• Bi BT, Lin HB, Cheng YF, et al. Promotion of β-amyloid production by C-reactive protein and its implications in the early pathogenesis of Alzheimer’s disease. Neurochem Int 2012;60:257-66
   PubMedGoogle Scholar
• Erratum The BACE race is on. Nat Rev Drug Discov 2014;13:165
   Web of Science ®Google Scholar
• Lilly. Available from: www.lilly.com/Pages/Home.aspx
   Google Scholar
• Freiherr J, Hallschmid M, Frey WH, et al. Intranasal Insulin as a Treatment for Alzheimer’s Disease: a Review of Basic Research and Clinical Evidence. CNS Drugs 2013;27:505-14
   PubMed Web of Science ®Google Scholar
• Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimer’s Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm. Takeda Pharmaceutical Company Limited Zinfandel Pharmaceuticals, Inc. 2013; Data retrieved on 5 June 2014
   Google Scholar
• 3-monnths study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition and Safety in Subjects with Alzheimer’s disease. Available from: http://clinicaltrials.gov/show/NCT01374438
   Google Scholar
• EVP-6124 for Treating Alzheimer’s Disease. Available from: www.nia.nih.gov/alzheimers/clinical-trials/evp-6124-treating-alzheimersdisease [Last accessed on 10 Jun 2014]
   Google Scholar
• Masangkay EG. Mitsubishi Tanabe And EnVivo Kickstart Phase III Trial Of Alzheimer’s Disease Treatment MT-4666. Available from: www.outsourcedpharma.com [Last accessed on 8 Jun 2014]
   Google Scholar
• Astrazeneca. Available from: www.astrazeneca.com
   Google Scholar
• TARGACEPT. Available from: www.targacept.com
   Google Scholar
• Abbvie. Available from: www.abbvie.com
   Google Scholar
• ADAMAS. Available from: www.adamaspharma.com
   Google Scholar
• Actavis. Available from: www.frx.com/
   Google Scholar
• Gsk. Available from: www.gsk.com
   Google Scholar
• Lundbeck. Available from: www.lundbeck.com
   Google Scholar
• Otsuka. Available from: www.otsuka.com
   Google Scholar
• Avineuro. Available from: www.avineuro.com
   Google Scholar
• Nanotherapeutics. Available from: www.nanotherapeutics.com
   Google Scholar
• Roche. Available from: www.roche.com
   Google Scholar
• SANOFI. Available from: http://en.sanofi.com/
   Google Scholar
• Aphios. Available from: www.aphios.com/
   Google Scholar
• Pfizer. Available from: www.pfizer.com
   Google Scholar
• QR Pharma. Available from: www.qrpharma.com
   Google Scholar
• GENERVON. Available from: www.genervon.com
   Google Scholar
• RESVERLOGIX. Available from: www.resverlogix.com
   Google Scholar
• Accera. Available from: www.accerapharma.com/
   Google Scholar
• Janimm. Available from: www.janimm.com
   Google Scholar
• Sunovion. Available from: www.sunovion.com
   Google Scholar
• Takeda. Available from: www.takeda.com
   Google Scholar
• T3D Therapeutics. Available from: http://www.t3dtherapeutics.com/
   Google Scholar
• Janssen. Available from: www.janssenrnd.com
   Google Scholar
• Affiris. Available from: www.affiris.com
   Google Scholar
• Archer Pharmaceuticals. Available from: www.archerpharma.com
   Google Scholar
• Astellas. Available from: www.astellas.com
   Google Scholar
• Janssen Pharmaceuticals, Inc. Available from: www.janssenpharmaceuticalsinc.com
   Google Scholar
• SHIONOGI INC. Available from: www.shionogi.com
   Google Scholar
• Eisai. Available from: www.eisai.com
   Google Scholar
• Biogenidec. Available from: www.biogenidec.com
   Google Scholar
• Bristol-Myers Squibb. Available from: www.bms.com
   Google Scholar
• NOVARTIS. Available from: www.novartis.com/
   Google Scholar
• MERCK. Available from: www.merck.com
   Google Scholar
• XEL Pharmaceuticals. Available from: www.xelpharmaceuticals.com
   Google Scholar
• Vivus. Available from: www.vivus.com
   Google Scholar
• TransTech Pharma. Available from: www.ttpharma.com
   Google Scholar
• FUJI FILM. Available from: www.toyama-chemical.co.jp
   Google Scholar
• Sonexa. Available from: www.sonexa.com
   Google Scholar
• SGC Pharma. Available from: www.sgcpharma.com
   Google Scholar
• Navidea. Available from: www.navidea.com
   Google Scholar
• Allon therapeutics. Available from: www.allontherapeutics.com
   Google Scholar
• Forum Pharmaceuticals. Available from: www.envivopharma.com
   Google Scholar
• Proteo Tech. Available from: www.proteotech.com
   Google Scholar
• SIEMENS. Available from: www.usa.healthcare.siemens.com
   Google Scholar
• GE Healthcare. Available from: www.gehealthcare.com
   Google Scholar
• Baxter. Available from: http://baxter.com/
   Google Scholar
• Highpointpharma. Available from: www.highpointpharma.com
   Google Scholar
• GRIFOLS. Available from: www grifols.com
   Google Scholar
• KAREUS Therapeutics; SA. Available from: www.kareustherapeutics.com
   Google Scholar
• TAU Rx Therapeutics. Available from: www.taurx.com
   Google Scholar
• Amarantus. Available from: www.amarantus.com
   Google Scholar
• AB-SCIENCE. Available from: www.ab-science.com
   Google Scholar
• Mithridion. Available from: www.mithridion.com
   Google Scholar
• Metabolic Solutions Development Company. Available from: www.msdrx.com
   Google Scholar
• Humanetics. Available from: www.humaneticscorp.com
   Google Scholar